Thus, combined studies on metagenomics and metabolomics, coupled with molecular pathways analysis, are essential to elucidate alterations in methionine metabolism and the implication for CDX2 gene downregulation during GIM progression to GC. The gene discussed is CDX2; the disease is gastric cancer.